|
Price: $71.7400
$-0.44 
-0.610%
|
| Day's High:
| $71.94
| Week Perf:
| -0.18 %
|
| Day's Low: |
$ 71.31 |
30 Day Perf: |
7.69 % |
| Volume (M): |
877 |
52 Wk High: |
$ 87.88 |
| Volume (M$): |
$ 62,880 |
52 Wk Avg: |
$77.27 |
| Open: |
$71.94 |
52 Wk Low: |
$64.02 |
|
|
| Market Capitalization (Millions $) |
17,876 |
| Shares
Outstanding (Millions) |
249 |
| Employees |
6,944 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
821 |
| Cash Flow (TTM) (Millions $) |
416 |
| Capital Exp. (TTM) (Millions $) |
92 |
Hologic Inc
Hologic Inc is a US-based medical technology company that specializes in diagnostic, surgical, and medical imaging equipment primarily for women's health. The company's headquarters are located in Marlborough, Massachusetts, and they have operations in over 50 countries globally.
The company was founded in 1985 and initially focused on developing osteoporosis diagnostic products. Since then, Hologic has expanded its scope and now offers a wide range of diagnostic and medical imaging equipment for cancer detection, gynecology, and skeletal health. They also provide surgical products and accessories for diagnostic imaging and breast biopsy procedures.
Hologic's imaging equipment is among the best in the industry, with the company providing the first-ever 3D mammography system, known as the Selenia Dimensions digital breast tomosynthesis (DBT) system, which was approved by the FDA in 2011. The system uses low-dose X-rays to provide multi-layered images of the breast, improving detection and decreasing the need for follow-up biopsies.
Hologic's advanced technologies also include the Panther Fusion system for molecular diagnostic testing, NovaSure for endometrial ablation to treat heavy menstrual bleeding, and MyoSure for removing uterine fibroids or polyps. Additionally, the company offers a range of products and services aimed at supporting women's health, including prenatal testing and infertility treatment.
Hologic's reputation in the medical industry is built on its commitment to quality and patient outcomes. They continue to invest in research and development, exploring innovative solutions that can improve women's health and transform the diagnostics and medical imaging industry as a whole.
In addition to their commitment to patient outcomes, the company also focuses on sustainability and corporate responsibility. They aim to reduce environmental impact, maintain ethical business practices, and promote diversity and inclusion in their workforce.
Overall, Hologic Inc is a leading medical technology company that offers cutting-edge diagnostic, surgical, and medical imaging equipment for women's health. They are dedicated to advancing medical technology, improving patient outcomes, and promoting corporate responsibility.
Company Address: 250 Campus Drive Marlborough 1752 MA
Company Phone Number: 263-2900 Stock Exchange / Ticker: NASDAQ HOLX
| HOLX is expected to report next financial results on January 31, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Hologic Inc
Hologic Inc, a leading Medical Laboratories company, recently released its financial results for the fiscal period ending September 30, 2023. The results indicated a significant decline in income and net profits compared to the previous year. Additionally, the company's operating and net margins contracted, while inventories and accounts receivable witnessed fluctuations. This article aims to outline the facts and interpret the financial performance of Hologic Inc in context.
Financial Results:
1. Income and Earnings Per Share (EPS):
- Hologic Inc's income for the most recent fiscal period fell by -22.69% to $0.36 per share, contrasting with $0.47 per share reported in the previous financial reporting period.
- In the preceding financial reporting period, the company recorded an income per share of $-0.16.
- The decline in EPS is noteworthy, as it has decreased by -64.33% to $1.83 per share from $5.13 per share in the preceding fiscal period.
|
|
Hh And L Acquisition Co
As the earnings cycle resumes for the fiscal period of July-September 2023, a number of entities have disclosed their financial results, including several constituents of the Medical Laboratories sector. One such company is Hh And L Acquisition Co (HHLAU), which recently reported an operating loss of $-4.59154 million for the financial interval ending September 30, 2023.
Analyzing HHLAU's Performance
To accurately assess the fiscal period ending in the third quarter of 2023, it is essential to compare it with its performance in the previous year. In Q3 2022, HHLAU recorded an operating loss of $-1.440693 million. The recent increase in operating loss raises concerns about the firm's ability to sustain and nurture potential revenue streams.
The Stakeholder Analysis
A net loss of $4.769 million in the most recent fiscal period raises several red flags for stakeholders of HHLAU. It suggests potential issues within the company's operations, financial management, or market positioning. Stakeholders, such as investors, lenders, and employees, must closely monitor the company's performance to make informed decisions regarding their involvement with HHLAU.
|
|
Absci Corp
Absci Corp: A Closer Look at the Third Quarter Earnings Report
Absci Corp, a generative AI drug creation company, recently released its earnings report for the third quarter of the 2023 earnings season. The report reveals both positive and negative aspects of the company's financial performance during this period.
To begin with, Absci Corp managed to decrease its loss per share to $-0.24 per share, compared to $-0.30 per share in the previous year. This improvement is a positive sign for shareholders, indicating that the company is taking steps to reduce its losses and move towards profitability.
|
|
Aclarion Inc
The stock market is a dynamic arena where investors scrutinize the financial performance of different companies to make informed investment decisions. Aclarion Inc, a Medical Laboratories company, has recently shared its fiscal results for the most recent reporting period. In this article, we will delve into the interesting facts surrounding the company's performance, analyzing its revenue growth, net shortfall, accounts receivable, and provide insights into its future prospects.
Revenue Growth and Market Position:
During the most recent fiscal period, Aclarion Inc reported reaching a flat valuation of $0.00 per share, which was consistent with the previous year's figure. However, it's worth noting that the company's revenue increased moderately by 4.626% to $0.02 million from the corresponding period a year ago. This positive revenue growth places Aclarion Inc in a favorable position within the Medical Laboratories industry, which witnessed an overall 4.27% top-line growth during the same period. Sequentially, Aclarion Inc's revenue advanced by 11.674% from the preceding financial reporting period, demonstrating its ability to sustain growth and expand its market share.
|
|
Opgen Inc
During the past 5 trading days, Opgen Inc's stock experienced a significant decrease of -16.27%. This dip brings the year-to-date performance to an impressive 184.36%. Currently, Opgen Inc's stock is trading on the NASDAQ at a value that is -39.6% below its 52-week average.
Recent financial reports from Opgen Inc show interesting developments. For the interval between July and September 30, 2023, OPGN's deficit has increased by $-0.46 per share when compared to the same period a year prior. On the other hand, the earnings per share have improved from $-0.93 per share in the preceding quarter. This indicates a mixed performance for the company's financial results.
|
| Per Share |
Current |
| Earnings (TTM) |
1.82 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
1.67 $ |
| Cash |
10.93 $
|
| Book Value |
20.13 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
1.82 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
1.67 $ |
| Cash |
10.93 $
|
| Book Value |
20.13 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
